Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2002
03/14/2002US20020031496 Therapy for cellular accumulation in chronic inflammatory diseases
03/14/2002US20020031493 Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
03/14/2002US20020031492 Providing a brain tumor sample, quantifying the expression of an interleukin-13 (IL-13) receptor in the sample; and correlating the quantity of expression of the IL-13 receptor with the tumor type or grade; prognosis
03/14/2002US20020031491 Stem cell factor: composition claims
03/14/2002DE10141749A1 Inhibiting or stimulating angiogenesis by modulating the kinin B1 receptor, useful e.g. for treating solid tumors, macular degeneration, diabetic retinopathy or cardiac infarction
03/14/2002DE10108463A1 Neue für das citA-Gen kodierende Nukleotidsequenzen New coding for the citA gene nucleotide sequences
03/14/2002DE10044027A1 New nucleic acid encoding preprotein of mistletoe lectin, useful as diagnostic and therapeutic agents, also encodes polypeptide
03/14/2002DE10043702A1 New antisense oligonucleotides and ribozymes, useful for treating e.g. pain and for diagnosis, are directed against mRNA for vanilloid-family receptors
03/14/2002DE10043227A1 Neuartiges entwicklungsbiologisches Gen Novel biological developmental gene
03/14/2002DE10043124A1 Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase Method for the diagnosis of neural disorders and for the treatment of primary hemostasis deficiency
03/14/2002DE10042137A1 sgk2 und sgk3 als diagnostische und therapeutische Targets sgk2 and sgk3 as diagnostic and therapeutic targets
03/14/2002DE10041478A1 Neue pharmazeutische Zusammensetzung New pharmaceutical composition
03/14/2002DE10030378A1 Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen New pharmaceutical composition for topical application of water-insoluble and / or poorly water-soluble drugs
03/14/2002CA2422506A1 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
03/14/2002CA2422204A1 Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice
03/14/2002CA2422157A1 Inhibitors of serine protease activity of matriptase or mtsp1
03/14/2002CA2422114A1 Novel human cancer/testis antigen and gene thereof
03/14/2002CA2421922A1 Proteases
03/14/2002CA2421872A1 Mechanism of mitochondrial membrane permeabilization by hiv-1 vpr, mimetics of vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of vpr with ant
03/14/2002CA2421842A1 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
03/14/2002CA2421840A1 Parietaria judaica ns-ltp antigen variants, uses thereof and compositions comprising them
03/14/2002CA2421783A1 Receptor in the edb fibronectin domain
03/14/2002CA2421760A1 G-csf analog compositions and methods
03/14/2002CA2421757A1 G-csf analog compositions and methods
03/14/2002CA2421723A1 Stat3 agonists and antagonists and therapeutic uses thereof
03/14/2002CA2421714A1 Improved bioactive whey protein hydrolysate
03/14/2002CA2421584A1 Gene therapy for cardiac arrythmias
03/14/2002CA2421581A1 Benzene tricarboxylic acid amides as insulin receptor activators
03/14/2002CA2421448A1 Hla binding peptides and their uses
03/14/2002CA2421445A1 Hla binding peptides and their uses
03/14/2002CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil)
03/14/2002CA2421374A1 Methods and compositions for diseases associated with amyloidosis
03/14/2002CA2421271A1 Human and mouse targeting peptides identified by phage display
03/14/2002CA2421265A1 Molecules for diagnostics and therapeutics
03/14/2002CA2421251A1 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
03/14/2002CA2421248A1 Test systems based on transmembrane receptors from helminths and the use thereof for identifying and characterizing compounds
03/14/2002CA2421218A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/14/2002CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides
03/14/2002CA2421195A1 Compositions and methods for targeting peptides in humans in vivo
03/14/2002CA2421191A1 Methods and compositions for in vitro targeting
03/14/2002CA2421183A1 Novel polypeptide and anti-hiv agent containing the same
03/14/2002CA2421172A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3
03/14/2002CA2421155A1 Osteoclast-associated receptor
03/14/2002CA2421075A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/14/2002CA2421070A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma
03/14/2002CA2421041A1 Caveolin peptides and their use as therapeutics
03/14/2002CA2421027A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/14/2002CA2420890A1 Antithrombotic compositions
03/14/2002CA2419979A1 Mammalian genes; related reagents and methods
03/14/2002CA2419943A1 Secretory molecules
03/14/2002CA2417660A1 Vp22 protein/nucleic acid aggregates, uses thereof
03/14/2002CA2417258A1 Flavoring systems for pharmaceutical compositions and methods of making such compositions
03/14/2002CA2412298A1 Extended native chemical ligation
03/14/2002CA2412279A1 "pseudo"-native chemical ligation
03/14/2002CA2412278A1 Polymer-modified synthetic proteins
03/14/2002CA2412277A1 Synthetic erythropoiesis stimulating proteins
03/14/2002CA2389739A1 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
03/13/2002EP1186665A1 A delivery method for the tumor specific apoptosis inducing activity of apoptin
03/13/2002EP1186663A1 Production of pluripotent granulocyte colony-stimulating factor
03/13/2002EP1186662A2 Prion binding proteins and uses thereof
03/13/2002EP1186661A1 Identification of the major capacitative calcium channel in antigen presenting cells and uses thereof
03/13/2002EP1186615A1 Novel protein and dna thereof
03/13/2002EP1186319A1 Use of serum response factor (SRF) modulator for treating SRF related diseases
03/13/2002EP1186304A2 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
03/13/2002EP1186301A2 Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
03/13/2002EP1186299A1 The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
03/13/2002EP1185862A2 Method and compositions relating to insulin resistance disorders
03/13/2002EP1185700A1 49 human secreted proteins
03/13/2002EP1185696A1 Antisense oligonucleotide modulation of human protein kinase c-delta expression
03/13/2002EP1185694A1 49 human secreted proteins
03/13/2002EP1185691A1 Neisseria genomic sequences and methods of their use
03/13/2002EP1185681A1 High specificity hairpin antisense oligonucleotides
03/13/2002EP1185673A2 Novel calpains and their use
03/13/2002EP1185666A1 Hyaluronidase from the hirudinaria manillensis, isolation, purification and recombinant method of production
03/13/2002EP1185664A2 CLONED GENONE OF INFECTIOUS HEPATITIS C VIRUS OF GENOTYPE 2a AND USES THEREOF
03/13/2002EP1185662A2 Dna vaccines for pets and sport animals
03/13/2002EP1185652A2 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
03/13/2002EP1185648A2 Methods and compositions for inhibiting neoplastic cell growth
03/13/2002EP1185645A1 Adipocyte complement related protein homolog zacrp7
03/13/2002EP1185643A1 Adipocyte complement related protein homolog zacrp5
03/13/2002EP1185642A2 Compositions and methods for the treatment of tumor
03/13/2002EP1185639A1 Prostate-specific gene, pcgem1, and methods of using pcgem1 to detect, treat, and prevent prostate cancer
03/13/2002EP1185637A1 ANTISENSE TO i c-myc /i FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
03/13/2002EP1185635A2 Non-human transgenic animals deficient in gas6 function and their use
03/13/2002EP1185634A1 Instant formulations of enzymes, used for animal feed
03/13/2002EP1185632A1 Caspase-8 crystals, models and methods
03/13/2002EP1185623A1 Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases for the conference of drug resistance and for the loss of drug resistance in biological systems and methods for the detection of ecto-phosphatase inhibitors
03/13/2002EP1185620A2 Spheroid preparation
03/13/2002EP1185615A2 Recombinant influenza viruses for vaccines and gene therapy
03/13/2002EP1185558A1 Peptide having preptin functionality
03/13/2002EP1185557A1 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
03/13/2002EP1185556A1 Use of soluble protein molecules expressed by the pancreas and kidney glomerulus
03/13/2002EP1185555A2 Compositions isolated from skin cells and methods for their use
03/13/2002EP1185554A1 Peptide having for fibrinogen fragment e activity, analogs, antibodies and uses thereof
03/13/2002EP1185553A1 Heart homing peptides and methods of using same
03/13/2002EP1185552A1 Retro-inverso peptides derived from interleukin-3
03/13/2002EP1185551A1 Method for purification of proteins
03/13/2002EP1185547A2 Gene expression modulated in gastrointestinal inflammation
03/13/2002EP1185545A1 Cd4-independent hiv envelope proteins as vaccines and therapeutics
03/13/2002EP1185543A1 50 human secreted proteins